Cargando…
Measurable residual disease in multiple myeloma: ready for clinical practice?
The landscape of multiple myeloma (MM) has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess measurable residual disease (MRD) as the most accurate method to evaluate treatment efficacy. The sensit...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310444/ https://www.ncbi.nlm.nih.gov/pubmed/32571377 http://dx.doi.org/10.1186/s13045-020-00911-4 |